| 2-MTHβC | 2-Methyl-1,2,3,4-tetrahydro-beta-carboline |
| 4-AcO-DALT | 4-Acetoxy-N, N-diallyltryptamine |
| 4-AcO-DET | 4-Acetoxy-N,N-diethyltryptamine |
| 4-AcO-DiPT | 4-Acetoxy-N, N- diisopropyltryptamine |
| 4-AcO-DMT | 4-Acetoxy-N,N-dimethyltryptamine |
| 4-AcO-DPT | 4-Acetoxy-N, N-dipropyltryptamine |
| 4-AcO-MET | 4-Acetoxy-N-methyl-N-ethyltryptamine |
| 4-HIAA | 4-Hydroxyindole acetic acid |
| 4-MeO-DMT | 4-Methoxy-N,N-dimethyltryptamine |
| 4-MeO-MiPT | 4-Methoxy-N-methyl-N-isopropyltryptamine |
| 4-OH-DET | 4-Hydroxy-diethyl-tryptamine |
| 4-OH-DMT | 4-Hydroxy-NN-dimethyltryptamine |
| 4-OH-DPT | 4-Hydroxy-N,N-dipropyltryptamine |
| 4-OH-MET | 4-Hydroxy-N-methyl-N-ethyltriptamine |
| 4-OH-MiPT | 4-Hydroxy-N-methyl-N-isopropyltryptamine |
| 4-OH-MPT | 4-Hydroxy-N-methyl-N-propyltryptamine |
| 4-OH-pyr-T | 4-Hydroxy-N,N-tetramethylenetryptamine |
| 5-HT | 5-Hydroxytryptamine |
| 5-MeO-DALT | 5-Methoxy-N,N-diallyltryptamine |
| 5-MeO-DET | 5-Methoxy-N,N-diethyltryptamine |
| 5-MeO-DiPT | 5-Methoxy-diisopropyltryptamine |
| 5-MeO-DMT | 5-Methoxy-N,N-dimethyltryptamine |
| 5-MeO-DPT | 5-Methoxy-N, N-dipropyltryptamine |
| 5-MeO-MET | 5-Methoxy-N-methyl-N-ethyltryptamine |
| 5-MeO-MiPT | 5-Methoxy-N-methyl-N-isopropyltryptamine |
| 5-MeO-MiPT-N-oxide | 5-Methoxy-N-methyl-N-isopropyltrypt-amine-N-oxide |
| 5-MeO-NiPT | 5-Methoxy-N-isopropyltryptamine |
| 5-MeO-TMT | 5-Methoxy-N,N-trimethyltryptamine |
| 5-MeO-α-MT | 5-Methoxy-alpha-methyltryptamine |
| 5-OH-DiPT | 5-Hydroxy-N,N-diisopropyltryptamine |
| 5-OH-DMT | 5-Hydroxy-N,N-dimethyltryptamine |
| 5-OH-MiPT | 5-Hydroxy-N-methyl-N-isopropyltryptamine |
| CNS | Central nervous system |
| DBS | Dried blood spots |
| DDA | Data dependent acquisition |
| DEA | Drug Enforcement Administration |
| DET | N,N-diethyltryptamine |
| DiPT | N,N-diisopropyltryptamine |
| DLLME | Dispersive liquid-liquid microextraction |
| DMT | N,N-dimethyltryptamine |
| DMT-NO | Dimethyltryptamine-N-oxide |
| DPT | N,N-dipropyltryptamine |
| ED | Emergency department |
| EMCDDA | European Monitoring Centre for Drugs and Drug Addiction |
| FDA | Food and Drug Administration |
| GC | Gas chromatography |
| GC-EI-TOF | Gas chromatography time-of-flight detection with electron impact ionization |
| GC-MS | Gas chromatography-mass spectrometry |
| GDS | Global Drug Survey |
| HPLC | High-performance liquid chromatography |
| HPLC-MS | High-performance liquid chromatography coupled with mass spectrometry |
| IAA | Indole-3-Acetic Acid |
| IM | Intramuscular |
| IV | Intravenous |
| LC | Liquid chromatography |
| LC–HRMS/MS | Liquid chromatography–high-resolution mass spectrometry |
| LC-MS/MS | Liquid chromatography coupled with mass spectrometry in |
| LLE | Liquid-liquid extraction |
| LOD | Limit of detection |
| LSD | Lysergic acid diethylamide |
| MAO | Monoamine oxidase |
| MAOI | Monoamine oxidase inhibitor |
| MDMA | 3,4-Methylenedioxymethamphetamine |
| MET | N-methyl-N-ethyltryptamine |
| MRM | Multiple reaction monitoring |
| NMT | N-methyltryptamine |
| NPS | New psychoactive substances |
| OH-5-MeO- MiPT | hydroxy-5-methoxy-N-methyl-N-isopropyl-tryptamine |
| PDA | Photodiode array acquisition |
| SIM | Single ion monitoring |
| SPE | Solid phase extraction |
| STAI | Speilberg State-Trait Anxiety Inventory |
| TOF | Time of flight |
| UHPLC-HRMS/MS | Ultra-performance liquid chromatography-high resolution mass spectrometry |
| UNODC | United Nations Office on Drugs and Crime |
| WHO | World Health Organization |
| α-ET | Alpha-ethyltryptamine |
| α-MT | Alpha-methyltryptamine |